(R)-tert-butyl 3-((benzofuran-7-yl)carbonyl)piperidine-1-carboxylate | 884512-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: (R)-tert-butyl 3-((benzofuran-7-yl)carbonyl)piperidine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-(1-benzofuran-7-carbonyl)piperidine-1-carboxylate
• CAS: 884512-44-1
• 化学式: C₁₉H₂₃NO₄
• 分子量: 329.396
• InChiKey: NRMRAVOCBINDNX-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  59.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 3-((benzofuran-7-yl)carbonyl)piperidine-1-carboxylate 、 magnesium,1-methoxybutane,chloride 在 盐酸 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 26.03h， 生成 (S)-1-(benzofuran-7-yl)-5-methoxy-1-((R)-piperidin-3-yl)pentan-1-ol
  参考文献：
  名称：

  [EN] PIPERIDINE AND MORPHOLINE RENIN INHIBITORS
  [FR] PIPÉRIDINE ET MORPHOLINE INHIBITEURS DE LA RÉNINE

  摘要：

  公开号：

  WO2007117560A3
• 作为产物：
  描述：

  (3R)-3-[(甲氧基甲基氨基)羰基]-1-哌啶羧酸 1,1-二甲基乙酯 在 碳酸氢钠 作用下， 以 四氢呋喃 、 hexanes 、 水 为溶剂， 反应 1.31h， 生成 (R)-tert-butyl 3-((benzofuran-7-yl)carbonyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] PIPERIDINE AND MORPHOLINE RENIN INHIBITORS
  [FR] PIPÉRIDINE ET MORPHOLINE INHIBITEURS DE LA RÉNINE

  摘要：

  公开号：

  WO2007117560A3

文献信息

• Diaminoalkane Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20090018103A1

  公开（公告）日：2009-01-15

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.

  公式I的Diaminoalkanes现已被发现，它们具有口服活性并结合到天冬氨酸蛋白酶以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性升高相关的疾病方面非常有用。本发明还涉及使用公式I化合物治疗或改善需要的天冬氨酸蛋白酶相关疾病的方法，包括向该受体施用公式I化合物的有效量。
• Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264428A1

  公开（公告）日：2009-10-22

  Described are compounds of the formula (I) which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

  本文描述了一种公式（I）的化合物，其具有口服活性并能结合天冬氨酸蛋白酶以抑制其活性。它们可用于治疗或改善与天冬氨酸蛋白酶活性相关的疾病。还描述了在需要改善或治疗天冬氨酸蛋白酶相关疾病的受试者中使用本文所述化合物的方法。
• Piperidine and Morpholine Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264432A1

  公开（公告）日：2009-10-22

  Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.

  描述了一些口服的化合物，它们能够结合到肾素并抑制其活性。它们在治疗或改善与肾素活性相关的疾病方面是有用的。同时描述了使用这些化合物治疗或改善受肾素介导的疾病的方法。
• RENIN INHIBITORS
  申请人：Baldwin John J.

  公开号：US20090275581A1

  公开（公告）日：2009-11-05

  Disclosed are compounds according to Formula I: wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.

  本发明涉及公式I所示的化合物，其中变量在此定义。这些化合物能够结合天冬氨酸蛋白酶以抑制其活性。它们可用于治疗或改善与天冬氨酸蛋白酶活性相关的疾病。本发明还描述了拮抗需要受到天冬氨酸蛋白酶抑制剂的受试者的方法，包括向受试者施用公式I所示的化合物的治疗有效量。
• Piperidine and morpholine renin inhibitors
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：US07858624B2

  公开（公告）日：2010-12-28

  Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.

  描述了一些口服活性化合物，它们能够结合到肾素上，从而抑制其活性。它们可用于治疗或缓解与肾素活性相关的疾病。同时，还描述了使用这些化合物治疗或缓解受体内肾素介导的疾病的方法。